AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 191 min read$DFTX

Director at Definium Therapeutics (DFTX) now holds 22,296 shares

Definium Therapeutics (DFTX) director Carol A. Vallone exercised stock options on September 18, 2026, acquiring 1,086 shares at $35.52 each. Post-transaction, she holds 22,296 shares directly. The exercised option position is now zero.

Original reporting
stocktitan.net
Published Sep 19, 2026, 2:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 4:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$DFTX
Neutral
medium confidence
Mentioned
$DFTX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

The filing provides a transparent view of insider holdings but does not introduce new corporate events.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

If the company is nearing a catalyst (e.g., trial data), even a modest insider buy might gain significance.

Relevance 4/10Novelty 4/10Timing: September 18, 2026 transaction date

Background

Definium Therapeutics filed a Form 4 reporting a director's option exercise and resulting share ownership.

Company-level read

Ticker impact

$DFTXNeutralMedium confidence
Context

Director Carol A. Vallone exercised stock options for 1,086 shares at $35.52, increasing her holding to 22,296 shares.

Expected impact

Minimal to no immediate impact; may be viewed as a modest confidence signal.

Evidence & confidence

The transaction size is modest for a micro‑cap; insider buying can be a positive sign but the amount is too small to drive price action.

Market effects

Sector

None; isolated insider transaction in a biotech micro‑cap.

Regional

None; limited to the company's shareholders.

Global

None

Counterpoint

What could challenge this read

The insider purchase could be a subtle vote of confidence, suggesting potential upside despite the small size.

Key entities

  • Director
    Carol A. Vallone

    Definium Therapeutics director who exercised options.

  • Company
    Definium Therapeutics, Inc.

    Biotech firm listed under ticker DFTX.

Read at source← All news

Related articles

SEP 23
$DFTXHighAI 9/10

Definium Therapeutics at TD Cowen summit: phase iii data lift dt120

Definium Therapeutics (DFTX) presented phase III data for DT120, showing statistically significant results in treating generalized anxiety disorder and major depressive disorder. The drug demonstrated placebo-adjusted improvements of 5.4, 5.1, and 8.1 points in respective studies, with rapid clearance. The company is preparing for pre-NDA talks with the FDA to discuss filing strategies. Response and remission rates were lower than phase II but still clinically meaningful.

investing.com2 min
SEP 20
$DFTXMedAI 8/10

Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for its LSD-based anxiety drug, DT120. The trial showed a 5.1-point improvement over placebo, similar to its previous trial. Psychedelic stocks often move together, and Definium's success could impact the broader sector. Hedge fund holdings of DFTX have increased, indicating growing institutional confidence.

yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study

Definium Therapeutics (DFTX) reported positive Phase III results for DT120 in treating anxiety, with 32% of patients showing significant improvement vs. 14% on placebo. The drug was well-tolerated, and the company plans to meet with the FDA in Q4, aiming for an NDA submission in early 2027. Definium has $1.1B in cash and is preparing for commercialization.

finance.yahoo.com2 min
SEP 19
$DFTXHighAI 9/10

Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The stock has surged 184.53% year-to-date, with a fair value estimate of $71.65, suggesting a 46% undervaluation. The company faces risks due to its pre-revenue status and reliance on DT120's success, with key Phase 3 readouts expected in 2026.

simplywall.st3 min
SEP 17
$DFTXMed

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

stocktwits.com2 min